TB-500 (Thymosin Beta-4): A Research Overview

Research-use context. This is an educational summary of the published preclinical literature for laboratory audiences. It is not medical advice, a dosing guide, or a recommendation for human use. TB-500 is investigational and not FDA-approved for human use, and is prohibited by WADA (2026 Prohibited List). All VANTA products are sold strictly for in-vitro and laboratory research use only.

What TB-500 is

TB-500 is a synthetic peptide based on the active region of Thymosin Beta-4 (Tβ4) — a naturally occurring 43-amino-acid peptide that is one of the most abundant actin-binding proteins in mammalian cells. The synthetic research peptide captures the active core of the parent molecule (commonly a ~7-residue fragment containing the LKKTET sequence implicated in its activity). It is supplied as a lyophilized powder for reconstitution in a laboratory setting.

A precise note researchers should keep in mind: most of the underlying literature studies Tβ4 itself; direct studies of the synthetic “TB-500” fragment are comparatively limited, and the two should not be treated as interchangeable without care.

Proposed mechanism in preclinical models

The molecular anchor of Tβ4 biology is G-actin sequestration — binding monomeric actin and regulating the pool available for filament formation. This cytoskeletal role is proposed to underlie its downstream activities:

• Cell migration. Regulation of the actin equilibrium is associated with keratinocyte and fibroblast migration into wound sites in preclinical models.
• Angiogenesis. Tβ4 has been reported to promote endothelial cell migration, tube formation, and progenitor-cell recruitment, with the LKKTET sequence specifically implicated in angiogenic activity.
• Inflammation modulation and matrix remodeling. Studies describe effects on inflammatory resolution and extracellular-matrix turnover.

What the literature does — and does not — establish

• Predominantly preclinical and mechanistic. A 2026 scoping review in Applied Sciences found the Tβ4/TB-500 evidence base weighted toward preclinical and mechanistic work, concentrated in wound/skin, vascular/endothelial, and ocular settings — with musculoskeletal tissues (tendon, ligament, cartilage) comparatively sparse.
• Tβ4 ≠ TB-500 in the data. That same review noted most interventions studied Tβ4 rather than TB-500, with direct TB-500 evidence limited to a single mixed experimental study.
• Some human work exists for Tβ4 formulations in specific indications (e.g. dry-eye disease), but TB-500 as the research-grade peptide remains investigational and unapproved.

Where TB-500 sits in the research landscape

TB-500 is frequently studied alongside BPC-157 in tissue-repair contexts, and is noted to have a comparatively more developed preclinical cardiac evidence base (e.g. post-infarction remodeling models). As with all cross-compound comparisons, researchers should consult the primary literature for each rather than generalize.

Laboratory handling

• Storage (lyophilized): cold, protected from light; long-term at −20 °C.
• After reconstitution: refrigerated (2–8 °C), used within the lab’s protocol window.
• Verification: confirm identity/purity against the batch COA (HPLC, mass spec).

VANTA supplies TB-500 as a ≥99% purity research peptide with a batch-specific COA. See our Certificates of Analysis page.

Frequently asked (research) questions

Is TB-500 the same as Thymosin Beta-4? No — TB-500 is a synthetic fragment based on Tβ4’s active region. Most published data studies the full Tβ4 peptide.

What does “actin-binding” have to do with healing? Actin dynamics govern cell movement; by regulating monomeric actin, Tβ4 is proposed to influence the cell migration central to tissue-repair models.

---

References

1. Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421–429.
2. Philp D, Kleinman HK. Animal studies with thymosin beta-4, a multifunctional tissue repair and regeneration peptide. Ann N Y Acad Sci. 2010;1194:81–86.
3. Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review. Applied Sciences (MDPI). 2026;16(12):6202. doi:10.3390/app16126202.
4. Sosne G, et al. Thymosin beta-4 promotes corneal wound healing and decreases inflammation in vivo. Exp Eye Res. (corneal model literature.)

Verify each source independently. This summary is research context only and does not describe or recommend human use.